Kenji Hirata, Shiro Watanabe, Hiroshi Wakabayashi, Kohsuke Kudo, Akihiro Nishie. PSMA Theranostics for Prostate Cancer: Evidence, Pitfalls, and Implementation in Japan. // International Journal of Urology. – 2026. – DOI: 10.1111/iju.70686. – URL: https://onlinelibrary.wiley.com/doi/10.1111/iju.70686?af=R
Kenji Hirata, Shiro Watanabe, Hiroshi Wakabayashi, Kohsuke Kudo, & Akihiro Nishie (2026). PSMA Theranostics for Prostate Cancer: Evidence, Pitfalls, and Implementation in Japan. International Journal of Urology. https://doi.org/10.1111/iju.70686
Kenji Hirata, et al. “PSMA Theranostics for Prostate Cancer: Evidence, Pitfalls, and Implementation in Japan.” International Journal of Urology, 2026. doi:10.1111/iju.70686.
@article{Hirata2026,
title = {PSMA Theranostics for Prostate Cancer: Evidence, Pitfalls, and Implementation in Japan},
author = {Hirata, Kenji and Watanabe, Shiro and Wakabayashi, Hiroshi and Kudo, Kohsuke and Nishie, Akihiro},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70686},
url = {https://onlinelibrary.wiley.com/doi/10.1111/iju.70686?af=R}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...